3 results about "Hyperparathyroidism" patented technology

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

The invention discloses a method for rapidly predicting an operation effect in a hyperparathyroidism operation, and belongs to the technical field of medical diagnosis. The invention develops a detection product and designs a novel method for rapidly predicting the surgical effect in hyperparathyroidism surgery, which comprises the following steps: respectively collecting blood samples before and after hyperparathyroidism surgery, and detecting the content of parathyroid hormone in the blood samples by adopting the detection product, obtaining an operation effect prediction result according to the change of the parathyroid hormone content before and after the operation; the detection product contains an anti-parathyroid hormone antibody secreted by a hybridoma cell strain with the preservation number of CCTCC (China Center For Type Culture Collection) No.2025122. According to the invention, the defects of long detection time and harsh sample requirements in the prior art are overcome, the change of the PTH content in the blood sample can be rapidly and accurately detected, whether hyperparathyroid gland excision is complete or not can be judged in an auxiliary manner, the detection time is shortened to 20 minutes, and the operation time is greatly shortened.

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.